Efficacy Studies providing efficacy data Table 5 shows studies which provided data for efficacy. Table 5. Studies which provided data for efficacy. All studies performed in COPD populations. Study Treatment No of arms (µg) (once daily unless otherwise specified N(n) 12 week and 24 week placebo controlled efficacy studies IIIa R, DB, 12 UMEC 125 69 yes and PG, (56) UMEC 62.5 safety PC 69 PLA (62) 68 (50) IIIa Safety R, DB, 24 UMEC 125 408 3361 efficacy PG, (312) VI 25 and PC 404 UMEC/VI (298) 125/25 PK 403 PLA (325) 277 (183) IIIa Safety R, DB, 24 UMEC 62.5 421 3373 efficacy PG, (324) VI 25 and PC 421 UMEC/VI (318) 62.5/25 PK 414 PLA (332) 280 (204) 24 week active comparator efficacy IIIa Safety R, DB, 24 UMEC 125 222 yes 3374 and DD, (165) UMEC/VI efficacy PG, 125/25 AC
Efficacy Studies providing efficacy data Table 5 shows studies which provided data for efficacy. Table 5. Studies which provided data for efficacy. All studies performed in COPD populations. Study Treatment arms (µg) (once daily unless otherwise specified No of N(n) 12 week and 24 week placebo controlled efficacy studies IIIa and safety R, DB, PG, PC 12 UMEC 125 UMEC 62.5 PLA 69 (56) 69 (62) 68 (50) yes IIIa Safety efficacy and PK R, DB, PG, PC 24 UMEC 125 VI 25 UMEC/VI 125/25 PLA 408 (312) 404 (298) 403 (325) 277 (183) IIIa Safety efficacy and PK R, DB, PG, PC 24 UMEC 62.5 VI 25 UMEC/VI 62.5/25 PLA 421 (324) 421 (318) 414 (332) 280 (204) 24 week active comparator efficacy IIIa Safety and efficacy R, DB, DD, PG, AC 24 UMEC 125 UMEC/VI 125/25 222 (165) yes 3361 3373 3374
auspar-umeclidinium-bromide-201500709.docx